This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Press releases

2020

eTheRNA immunotherapies & Frame Therapeutics are awarded EUR 1.9 million Eurostars research grant for their novel cancer vaccine collaboration

eTheRNA and China Grand Pharma enter a strategic collaboration in the Greater China Region focused on eTheRNA’s proprietary mRNA development products and manufacturing capabilities

eTheRNA extends mRNA contract manufacturing services

eTheRNA extends senior management team with appointment of Michael Mulqueen as VP Business Development

eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

Frame Therapeutics and eTheRNA immunotherapies NV open a new research collaboration to develop mRNA cancer vaccines against immunogenic neoantigens

eTheRNA Launches an International Consortium and Starts Development of Cross-strain Protective CoV-2 mRNA Vaccine for High Risk Populations

Our Address

Our Mailbox

Our Phone